Safety of Seasonal Malaria Chemoprevention (SMC) with Sulfadoxine-Pyrimethamine plus Amodiaquine when Delivered to Children under 10 Years of Age by District Health Services in Senegal: Results from a Stepped-Wedge Cluster Randomized Trial
Open Access
- 20 October 2016
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 11 (10), e0162563
- https://doi.org/10.1371/journal.pone.0162563
Abstract
It is recommended that children aged 3 months to five years of age living in areas of seasonal transmission in the sub-Sahel should receive Seasonal Malaria Chemoprevention (SMC) with sulfadoxine-pyrimethamine plus amodiaquine (SPAQ) during the malaria transmission season. The purpose of this study was to evaluate the safety of SMC with SPAQ in children when delivered by community health workers in three districts in Senegal where SMC was introduced over three years, in children from 3 months of age to five years of age in the first year, then in children up to 10 years of age. A surveillance system was established to record all deaths and all malaria cases diagnosed at health facilities and a pharmacovigilance system was established to detect adverse drug reactions. Health posts were randomized to introduce SMC in a stepped wedge design. SMC with SPAQ was administered once per month from September to November, by nine health-posts in 2008, by 27 in 2009 and by 45 in 2010. After three years, 780,000 documented courses of SMC had been administered. High coverage was achieved. No serious adverse events attributable to the intervention were detected, despite a high level of surveillance. SMC is being implemented in countries of the sub-Sahel for children under 5 years of age, but in some areas the age distribution of cases of malaria may justify extending this age limit, as has been done in Senegal. Our results show that SMC is well tolerated in children under five and in older children. However, pharmacovigilance should be maintained where SMC is implemented and provision for strengthening national pharmacovigilance systems should be included in plans for SMC implementation. ClinicalTrials.gov NCT 00712374Keywords
Funding Information
- Bill and Melinda Gates Foundation (40099)
This publication has 18 references indexed in Scilit:
- Safety monitoring of artemisinin combination therapy through a national pharmacovigilance system in an endemic malaria settingMalaria Journal, 2013
- Pharmacovigilance of Malaria Intermittent Preventive Treatment in Infants Coupled With Routine Immunizations in 6 African CountriesThe Journal of Infectious Diseases, 2012
- New Malaria-Control Policies and Child Mortality in Senegal: Reaching Millennium Development Goal 4The Journal of Infectious Diseases, 2012
- A Systematic Review and Meta-Analysis of the Efficacy and Safety of Intermittent Preventive Treatment of Malaria in Children (IPTc)PLOS ONE, 2011
- Amodiaquine Dosage and Tolerability for Intermittent Preventive Treatment To Prevent Malaria in ChildrenAntimicrobial Agents and Chemotherapy, 2010
- Characterisation of CYP2C8, CYP2C9 and CYP2C19 polymorphisms in a Ghanaian populationBMC Medical Genetics, 2009
- Effect of Concomitant Artesunate Administration and Cytochrome P4502C8 Polymorphisms on the Pharmacokinetics of Amodiaquine in Ghanaian Children with Uncomplicated MalariaAntimicrobial Agents and Chemotherapy, 2008
- Idiosyncratic drug-induced agranulocytosis or acute neutropeniaCurrent Opinion in Hematology, 2008
- Short communication: High prevalence of the cytochrome P450 2C8*2 mutation in Northern GhanaTropical Medicine & International Health, 2005
- Fatal Hepatic Necrosis Due to Pyrimethamine-Sulfadoxine (Fansidar)Annals of Internal Medicine, 1987